ResearcherUniversity of Chieti-PescaraActive in the last 2 years
Serena Veschi
Matched on ORCID iD 0000-0003-0450-9210; OpenAlex author ID A5065999376. Sources: OpenAlex.
Their work
- Papers
- 10 (first author 2, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 13
2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper
Papers 10
- Editorial: Exploring microbial interactions in pancreatic ductal adenocarcinoma microenvironment. Co-author DOI 10.3389/fonc.2025.1725126↗
- Exploring the Immunomodulatory Potential of Pancreatic Cancer-Derived Extracellular Vesicles through Proteomic and Functional Analyses. Last author DOI 10.3390/cancers16101795↗
- Resveratrol Derivative Exhibits Marked Antiproliferative Actions, Affecting Stemness in Pancreatic Cancer Cells. Co-author DOI 10.3390/ijms24031977↗
- High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results f… Co-author DOI 10.3390/cancers14194748↗
- Exosomes as Pleiotropic Players in Pancreatic Cancer. Last author DOI 10.3390/biomedicines9030275↗
- Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates. First author DOI 10.3390/cancers13163946↗
- Synthesis and evaluation of a large library of nitroxoline derivatives as pancreatic cancer antiproliferative agents. Co-author DOI 10.1080/14756366.2020.1780228↗
- The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective. Co-author DOI 10.3390/cancers12071849↗
- The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer. First author DOI 10.3390/cancers11122042↗
- Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells. Co-author DOI 10.1186/s13046-018-0904-2↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Rosalba Florio · 9 shared papers, 2018–2024 · strength 1.09
- Paper Exploring the Immunomodulatory Potential of Pancreatic Cancer-Derived Extracellular Vesicles through Proteomic and Func… DOI 10.3390/cancers16101795↗
- Paper Resveratrol Derivative Exhibits Marked Antiproliferative Actions, Affecting Stemness in Pancreatic Cancer Cells. DOI 10.3390/ijms24031977↗
- Paper Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates. DOI 10.3390/cancers13163946↗
- Laura De Lellis · 9 shared papers, 2018–2024 · strength 1.09
- Paper Exploring the Immunomodulatory Potential of Pancreatic Cancer-Derived Extracellular Vesicles through Proteomic and Func… DOI 10.3390/cancers16101795↗
- Paper Resveratrol Derivative Exhibits Marked Antiproliferative Actions, Affecting Stemness in Pancreatic Cancer Cells. DOI 10.3390/ijms24031977↗
- Paper Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates. DOI 10.3390/cancers13163946↗
- Alessandro Cama · 9 shared papers, 2018–2024 · strength 1.09
- Paper Exploring the Immunomodulatory Potential of Pancreatic Cancer-Derived Extracellular Vesicles through Proteomic and Func… DOI 10.3390/cancers16101795↗
- Paper Resveratrol Derivative Exhibits Marked Antiproliferative Actions, Affecting Stemness in Pancreatic Cancer Cells. DOI 10.3390/ijms24031977↗
- Paper Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates. DOI 10.3390/cancers13163946↗
- Davide Brocco · 7 shared papers, 2020–2024 · strength 0.94
- Paper Exploring the Immunomodulatory Potential of Pancreatic Cancer-Derived Extracellular Vesicles through Proteomic and Func… DOI 10.3390/cancers16101795↗
- Paper Resveratrol Derivative Exhibits Marked Antiproliferative Actions, Affecting Stemness in Pancreatic Cancer Cells. DOI 10.3390/ijms24031977↗
- Paper Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates. DOI 10.3390/cancers13163946↗
- Nicola Tinari · 6 shared papers, 2018–2022 · strength 0.66
- Paper Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates. DOI 10.3390/cancers13163946↗
- Paper Exosomes as Pleiotropic Players in Pancreatic Cancer. DOI 10.3390/biomedicines9030275↗
- Paper The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective. DOI 10.3390/cancers12071849↗
- Pierluigi Di Sebastiano · 3 shared papers, 2018–2025 · strength 0.61
- Paper Editorial: Exploring microbial interactions in pancreatic ductal adenocarcinoma microenvironment. DOI 10.3389/fonc.2025.1725126↗
- Paper High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Pa… DOI 10.3390/cancers14194748↗
- Paper Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in p… DOI 10.1186/s13046-018-0904-2↗
- Paola Lanuti · 4 shared papers, 2018–2024 · strength 0.52
- Paper Exploring the Immunomodulatory Potential of Pancreatic Cancer-Derived Extracellular Vesicles through Proteomic and Func… DOI 10.3390/cancers16101795↗
- Paper Resveratrol Derivative Exhibits Marked Antiproliferative Actions, Affecting Stemness in Pancreatic Cancer Cells. DOI 10.3390/ijms24031977↗
- Paper High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Pa… DOI 10.3390/cancers14194748↗
- Gabriella Mincione · 1 shared paper, 2025 · strength 0.42
- Rosa Amoroso · 2 shared papers, 2019–2023 · strength 0.24
- Paper Resveratrol Derivative Exhibits Marked Antiproliferative Actions, Affecting Stemness in Pancreatic Cancer Cells. DOI 10.3390/ijms24031977↗
- Paper The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Panc… DOI 10.3390/cancers11122042↗
- Anna Piro · 1 shared paper, 2024 · strength 0.16
- Zhirajr Mokini · 1 shared paper, 2021 · strength 0.13
- Fabio F. di Mola · 1 shared paper, 2022 · strength 0.11
- Clara Natoli · 1 shared paper, 2018 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.